Conjunctival mass as an initial presentation of mantle cell lymphoma: a case report
© Khanlari et al.; licensee BioMed Central Ltd. 2012
Received: 4 August 2012
Accepted: 15 October 2012
Published: 4 December 2012
To describe a rare manifestation of mantle cell lymphoma (MCL) in conjunctiva, with clinical, hisologic, immunohistologic and genetic findings together with review of the Literature.
Most ocular adnexal lymphomas are extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT). A few cases of ocular adnexal mantle cell lymphomas have been reported in the literature. We present a case of mantle cell lymphoma presenting as right conjunctival mass of at least three months duration in a 64-year-old man. Histopathologic examination showed a proliferation of monomorphous small-to-medium-sized lymphoid cells with cleaved nuclei in the subconjunctiva. By immunohistochemistry, the infiltrate was positive for CD20, CD5, BCL-2, cyclin D1, and the transcription factor SOX11. Fluorescent in situ hybridization demonstrated the presence of IGH-CCND1 fusion indicating t(11;14).
A rigorous approach to initial diagnosis and staging of small cell lymphomas of the ocular adnexa is needed. The recognition of ocular MCL requires appropriate immunohistochemical staining and/or genetic confirmation to differentiate this rare form of presentation of MCL from other more frequent small cell lymphomas.
Ocular adnexal lymphomas (OALs) are the most common orbital neoplasms in adults, accounting for about 55% of all malignant orbital lesions [1, 2]. About 80–90% of primary ocular adnexal lymphomas are extranodal marginal zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT), which can arise within the intraconal and extraconal orbital fat, lacrimal gland, extraocular muscles, lacrimal sac, lids or conjunctiva . Mantle cell lymphoma (MCL) is a relatively rare lymphoma, accounting for less than 10% of all lymphomas. In the ocular adnexal region, including rare cases of conjunctiva, MCL accounts for between 1-5%  and 9% of the lymphomas . The orbit is the most commonly involved site of MCL involvement, followed by the lacrimal gland and the eyelid, similar to extranodal marginal zone lymphoma in this region . Mantle cell lymphomas presenting in the ocular adnexal region have a male predominance and are associated with extraorbital extension at the time of diagnosis, advanced stage disease, short median progression-free survival (PFS), and older-age at diagnosis [6, 7]. In rare case reports, a higher frequency of these tumors fail to co-express CD5, rendering differential diagnosis between conjunctival mantle cell lymphoma from extranodal marginal zone B-cell lymphomas of MALT more difficult . We here report a case of MCL of the conjunctiva, as the first clinical presentation of advanced-stage mantle cell lymphoma, with extraocular lymph node and bone marrow involvement and review the literature in this field.
“Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.”
Ocular adnexal lymphomas (OAL) account for 2% of all non-Hodgkin lymphomas, and about 6-8% of extranodal lymphomas . The primary involvement of the conjunctiva by lymphoma, comprises about one third of ocular adnexal lymphoma, and 1.5% of all conjunctival tumors. Like other primary ocular adnexal lymphomas, most of the primary conjunctival lymphomas are low-grade extranodal marginal zone B-cell lymphomas of MALT. Other types of lymphomas such as diffuse large-cell lymphoma, mantle cell lymphoma, and more aggressive histologic subtypes are less commonly seen . It seems that, MCL in the ocular adnexal region is associated with poorer prognosis compared with the much more common extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue type in the same region. Of the ocular adnexal MCL, 80% present in stage III/IV. The median overall survival has been reported to be only 57 months .
According to the largest published series (n=21) of ocular adnexal MCL including six cases with conjunctival localization, patients with involvement of the orbital and adnexal region as first presenting symptom (n=14) had more frequently bilateral eye and bone marrow involvement, and inferior OS as opposed to patients with secondary ocular adnexal MCL (n=7) . The majority of patients in this series presented with stage IV disease with nodal- and bone-marrow involvement, although all patients were allocated in the low-risk group according to the MCL International Prognostic Index score.
In multiple studies, patients with lymphoma of conjunctival localization had a better outcome than lymphomas of other areas of the eye considering both local and systemic relapse . Only 31% patients with conjunctival lymphoid tumors showed systemic lymphoma, with fewer progressions than those involving other areas of the orbit . However, in recent studies conjunctival lymphomas with nodal involvement have a worse prognosis, and systemic disease is more common in patients with lymphomas located at an extralimbal site (ie, in the fornix or midbulbar region) [1, 12]. A study analyzing prognostic factors exclusively for low grade conjunctival non-Hodgkin’s lymphoma identified four prognostic factors for lower disease-free survival (DFS) and overall survival (OS) in the univariate analysis, namely age greater than 59 years, nodal involvement, stage IV, and an elevated IPI, but only the nodal involvement maintained the negative impact on DFS in multivariate analysis .
OAL are a distinct form of clinical presentations of several types of lymphomas including MZL or MCL. Since the majority of patients with OALs initially present to ophthalmologists, the current subdivision of OALs to primary versus secondary adnexal lymphomas, based on limited eye involvement (by imaging) and evidence of disease dissemination or previous history of lymphoma, is not practical, and the frequency of systemic dissemination at the time of diagnosis in patients who present with initial ocular complaints is largely unknown . In line with this, our case although had initially presented with occular lymphoma limited to conjunctiva, but due to inadequate workup by ophthalmologist and loosing follow up, subdividing our case to primary or secondary was not possible. Our case expressed nuclear SOX11 and cyclin-D1, as most classical MCLs. SOX11 negative MCLs are mainly leukemic and have a non-nodal presentation. Although nodal dissemination in SOX11 negative patients may occur and they are usually associated with TP53 mutation protein expression and more aggressive behavior .
In conclusion, a rigorous approach to initial diagnosis and staging of small cell lymphomas of the ocular adnexa is needed. The recognition of ocular MCL requires appropriate immunohistochemical staining and/or genetic confirmation to differentiate this rare form of presentation of MCL from other more frequent small cell lymphomas. Also according to TNM staging of ocular lymphomas, orbital imaging as well as systemic workup is suggested for these rare ocular presentations.
We like to thank Prof. E. Campo for performing SOX-11 and reviewing this case and paper, Prof. R. Siebert for performing FISH test for IGH-CCND1 fusion and revising this paper, Prof. W. Klapper for reviewing this case and his scientific comments.
- Shields JA, Shields CL, Scartozzi R: Survey of 1264 patients with orbital tumors and simulating lesions: The 2002 Montgomery Lecture, part 1. Ophthalmology. 2004, 111 (5): 997-1008. 10.1016/j.ophtha.2003.01.002.PubMedView ArticleGoogle Scholar
- Moslehi R, Devesa SS, Schairer C, Fraumeni JF: Rapidly increasing incidence of ocular non-hodgkin lymphoma. J Natl Cancer Inst. 2006, 98 (13): 936-939. 10.1093/jnci/djj248.PubMedView ArticleGoogle Scholar
- Cahill M, Barnes C, Moriarty P, Daly P, Kennedy S: Ocular adnexal lymphoma-comparison of MALT lymphoma with other histological types. Br J Ophthalmol. 1999, 83 (6): 742-747. 10.1136/bjo.83.6.742.PubMedPubMed CentralView ArticleGoogle Scholar
- Coupland SE, Hellmich M, Auw-Haedrich C, Lee WR, Stein H: Prognostic value of cell-cycle markers in ocular adnexal lymphoma: an assessment of 230 cases. Graefes Arch Clin Exp Ophthalmol. 2004, 242 (2): 130-145. 10.1007/s00417-003-0831-5.PubMedView ArticleGoogle Scholar
- Rasmussen P, Sjö LD, Prause JU, Ralfkiaer E, Heegaard S: Mantle cell lymphoma in the orbital and adnexal region. Br J Ophthalmol. 2009, 93 (8): 1047-1051. 10.1136/bjo.2008.146910.PubMedView ArticleGoogle Scholar
- Looi A, Gascoyne RD, Chhanabhai M, Connors JM, Rootman J: White VA Mantle cell lymphoma in the ocular adnexal region. Ophthalmology. 2005, 112 (1): 114-119. 10.1016/j.ophtha.2004.07.025.PubMedView ArticleGoogle Scholar
- Jenkins C, Rose GE, Bunce C, Wright JE, Cree IA, Plowman N, Lightman S, Moseley I, Norton A: Histological features of ocular adnexal lymphoma(REAL classification) and their association with patient morbidity and survival. Br J Ophthalmol. 2000, 84 (8): 907-913. 10.1136/bjo.84.8.907.PubMedPubMed CentralView ArticleGoogle Scholar
- Yoo SB, Kim YA, Jeon YK, Kim CW: CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report. Pathol Res Pract. 2008, 204 (10): 779-783. 10.1016/j.prp.2008.04.009.PubMedView ArticleGoogle Scholar
- Mozos A, Royo C, Hartmann E, De Jong D, Baró C, Valera A, Fu K, Weisenburger DD, Delabie J, Chuang SS, Jaffe ES, Ruiz-Marcellan C, Dave S, Rimsza L, Braziel R, Gascoyne RD, Solé F, López-Guillermo A, Colomer D, Staudt LM, Rosenwald A, Ott G, Jares P, Campo E: SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009, 94 (11): 1555-1562. 10.3324/haematol.2009.010264.PubMedPubMed CentralView ArticleGoogle Scholar
- Hatef E, Roberts D, McLaughlin P, Pro B, Esmaeli B: Prevalence and nature of systemic involvement and stage at initial examination in patients with orbital and ocular. Arch Ophthalmol. 2007, 125 (12): 1663-1667. 10.1001/archopht.125.12.1663.PubMedView ArticleGoogle Scholar
- Ferreri AJ, Govi S, Colucci A, Crocchiolo R, Modorati G: Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas. Ophthalmology. 2011, 118: 24-28. 10.1016/j.ophtha.2010.04.036.PubMedView ArticleGoogle Scholar
- Meunier J, Lumbroso-Le Rouïc L, Dendale R, Vincent-Salomon A, Asselain B, Arnaud P, Némati F, Fourquet A, Desjardins L, Plancher C, Levy C, Chaoui D, Validire P, Decaudin D: Conjunctival low-grade non-Hodgkin's lymphoma: a large single-center study of initial characteristics, natural history and prognostic factors. Leuk Lymphoma. 2006, 47 (7): 1295-1305. 10.1080/10428190500518966.PubMedView ArticleGoogle Scholar
- Rosado MF, Byrne GE, Ding F, Fields KA, Ruiz P, Dubovy SR, Walker GR, Markoe A, Lossos IS: Ocular adnexal lymphoma: a clinicopathologic study of a large cohort of patients with no evidence for an association with Chlamydia psittaci. Blood. 2006, 107 (2): 467-472. 10.1182/blood-2005-06-2332.PubMedPubMed CentralView ArticleGoogle Scholar
- Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B: Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood. 2012, 119 (18): 4215-4223. 10.1182/blood-2011-12-400580.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.